HHS Seeks Early Win Defending Medicare Drug Price Program
Boehringer Ingelheim and other drugmakers are free to take their business elsewhere if they object to the new Medicare price negotiation program, the federal government has said, urging a judge to...To view the full article, register now.
Already a subscriber? Click here to view full article